Pregnancy Clinical Trial
Official title:
A Randomized, Controlled Trial of the Efficacy, Safety, and Acceptability of BufferGel
BufferGel is a new contraceptive gel designed to be used with a diaphragm. In addition to preventing pregnancy, BufferGel may also prevent some types of sexually transmitted diseases (STDs). This study will compare BufferGel to Gynol II, a currently available contraceptive gel.
Vaginal acidity is thought to be one means by which the vagina prevents overgrowth or
colonization by harmful microbial flora. Sperm and many STD pathogens, including HSV-1 and
HSV-2, Neisseria gonorrhoeae, Treponema pallidum, Haemophilus ducreyi, and a variety of
bacterial vaginosis-associated bacteria, are inactivated at pH less than 5 in vitro.
BufferGel, a vaginal spermicide and microbicide, is an acidic buffer that maintains the
vagina at or near its natural state of mild acidity. Formulated at vaginal pH (pH 3.9),
BufferGel prevents or limits the semen-induced rise in vaginal pH. Carbopol 974P, the
buffering agent in BufferGel, is a high molecular weight, cross-linked, polyacrylic acid
used as a gelling or tableting agent in many pharmaceuticals; it has a well-documented
record of mucosal safety in animals and humans. This study will determine the safety and
contraceptive efficacy of BufferGel spermicide used with a diaphragm compared to Gynol II
spermicide used with a diaphragm. The study will also measure the frequency of bacterial
vaginosis, urinary tract infections, and cervical lesions in women using BufferGel compared
with Gynol II.
Participants in this study will be fitted for a diaphragm and randomized to receive either
BufferGel or Gynol II. All participants will be instructed on the use of the test product
with the diaphragm. Participants will be followed through 6 menstrual cycles (approximately
7 months) and will have 4 study visits and one study phone call. Some participants may
enroll in an extended version of the study and be followed for an additional 6 cycles and 2
additional study visits. Study visits will include a gynecologic exam, Pap smear, and blood
and urine tests. Participants will be asked to keep a diary to record information on product
use. Some participants may also be asked to enroll in a colposcopy substudy. These
participants will undergo colposcopy at study entry and after cycles 1, 3 and 6.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03442582 -
Afluria Pregnancy Registry
|
||
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Enrolling by invitation |
NCT05415371 -
Persistent Poverty Counties Pregnant Women With Medicaid
|
N/A | |
Completed |
NCT04548102 -
Effects of Fetal Movement Counting on Maternal and Fetal Outcome Among High Risk Pregnant Woman
|
N/A | |
Completed |
NCT03218956 -
Protein Requirement During Lactation
|
N/A | |
Completed |
NCT02191605 -
Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy
|
N/A | |
Completed |
NCT02223637 -
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
|
||
Recruiting |
NCT06049953 -
Maternal And Infant Antipsychotic Study
|
||
Completed |
NCT02577536 -
PregSource: Crowdsourcing to Understand Pregnancy
|
||
Not yet recruiting |
NCT06336434 -
CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04786587 -
Alcohol Self-reporting During Pregnancy. AUTOQUEST Study.
|
||
Not yet recruiting |
NCT05412238 -
Formulation and Evaluation of the Efficacy of Macro- and Micronutrient Sachets on Pregnant Mothers and Children Aged 6-60 Months
|
N/A | |
Not yet recruiting |
NCT05028387 -
Telemedicine Medical Abortion Service Using the "No-test" Protocol in Ukraine and Uzbekistan.
|
||
Completed |
NCT02783170 -
Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women
|
Phase 4 | |
Completed |
NCT02683005 -
Study of Hepatitis C Treatment During Pregnancy
|
Phase 1 | |
Recruiting |
NCT02619188 -
Nutritional Markers in Normal and Hyperemesis Pregnancies
|
N/A | |
Recruiting |
NCT02507180 -
Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
|
||
Recruiting |
NCT02564250 -
Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women
|
N/A | |
Completed |
NCT02523755 -
Evaluation of Regional Distribution of Ventilation During Labor With or Without Epidural Analgesia
|
Phase 4 |